Published online Aug 27, 2021. doi: 10.4240/wjgs.v13.i8.756
Peer-review started: January 12, 2021
First decision: March 30, 2021
Revised: April 6, 2021
Accepted: July 6, 2021
Article in press: July 6, 2021
Published online: August 27, 2021
Processing time: 219 Days and 19.5 Hours
Surgical resection for colorectal liver metastases (CRLM) may offer the best opportunity to improve prognosis. However, only about 20% of CRLM cases are indicated for resection at the time of diagnosis (initially resectable), and the remaining cases are treated as unresectable (initially unresectable). Thanks to recent remarkable developments in chemotherapy, interventional radiology, and surgical techniques, the resectability of CRLM is expanding. However, some metastases are technically resectable but oncologically questionable for upfront surgery. In pancreatic cancer, such cases are categorized as “borderline resecta
Core Tip: At this stage, a clear definition and treatment policy for borderline resectable colorectal liver metastases has not been established. According to previous reports, borderline resectable for colorectal liver metastases is oncologically highly malignant (simultaneous liver metastasis, multiple tumors, large tumor diameter, high level of carcinoembryonic antigen, extrahepatic lesions) or technically difficult (necessity of special procedures such as radiofrequency ablation, portal vein embolization, two-stage hepatectomy, and associating liver partition and portal vein ligation for staged hepa